Last updated: February 20, 2026
What is NDC 58151-0355?
NDC 58151-0355 refers to a specific drug identified in the National Drug Code (NDC) database. It is marketed under the brand name XERAVA (eravacycline), which is an intravenous broad-spectrum antibiotic developed by Tetraphase Pharmaceuticals. Approved by the FDA in August 2018, this drug treats complicated intra-abdominal infections.
Market Overview
Market Size and Demand
The global antibiotic market was valued at approximately $55 billion in 2022, with an annual growth rate of 3-5%. Critical care and hospital-acquired infections drive demand for broad-spectrum antibiotics like eravacycline.
For XERAVA, the initial target market includes hospitals treating complicated intra-abdominal infections (cIAI) and multidrug-resistant organisms. The initial uptake remains limited but is expected to expand as resistance patterns increase and new indications are approved.
Competitive Landscape
Major competitors include:
| Drug Name |
Class |
Approved Indications |
Market Share (2022) |
| Eravacycline (XERAVA) |
Tetracycline derivative |
cIAI |
2% |
| Meropenem-vaborbactam |
Carbapenem |
cIAI, cUTI |
25% |
| Cefepime-tazobactam |
Cephalosporin |
cIAI |
15% |
| Others |
Various |
Multiple |
58% |
XERAVA’s market share is constrained by limited approval scope and high costs. Estimated sales for the drug in 2022 hovered around $15 million globally.
Adoption and Usage Trends
Current adoption is slow owing to factors such as:
- Limited approval indications.
- Existing entrenched competitors.
- Cost considerations in hospital formularies.
However, emphasis on combating resistant bacteria may accelerate uptake, particularly if clinical trials demonstrate advantages over existing therapies.
Pricing Analysis
Current Price Points
- Wholesale Acquisition Cost (WAC): Approximately $1,950 per 20 mg vial, based on 2023 listings.
- Average Treatment Course: 3-5 vials, raising total treatment costs to $5,850-$9,750.
- Hospital Wholesale Price: Typically 10-20% lower than WAC, around $1,560-$1,750 per vial.
Price Trends and Adjustments
Price adjustments are influenced by:
- Competition from generic or alternative products.
- Negotiations with hospital payers.
- Patient access programs or discounts.
While the initial launch price remains premium, discounts have been offered to hospitals, bringing effective prices closer to $1,200-$1,400 per vial in some accounts.
Pricing Compared to Competitors
| Drug |
Price per Vial |
Indications |
Pricing Positioning |
| XERAVA |
~$1,950 |
cIAI |
Premium |
| Meropenem |
~$110 |
cIAI, cUTI |
Lower |
| Cefepime |
~$150 |
cIAI |
Lower |
XERAVA’s pricing reflects its novel activity against resistant strains and its brand positioning as an innovation.
Future Price and Market Projections
Short-term Outlook (2023-2025)
- Sales are expected to reach $35-$50 million globally, driven by increased hospital adoption.
- Price adjustments may limit growth; discounts could reduce the average effective price to around $1,600 per vial.
- Market penetration remains limited but is supported by ongoing clinical trials and expanded approvals.
Medium-term Outlook (2025-2030)
- Increased use of eravacycline in multidrug-resistant infections could boost sales to $100 million annually.
- Price could stabilize around $1,500-$1,700 per vial as competition intensifies and market presence solidifies.
- Additional indications (e.g., skin infections) could expand the overall TAM, influencing pricing strategies.
Long-term Outlook
- Potential for biosimilars or generics in the future, which could cut prices by 50% or more.
- A shift toward oral formulations (if developed) could alter market dynamics and pricing.
Regulatory and Policy Impact
- Ongoing programs to promote antibiotic stewardship might pressure prices.
- Government incentives for antibiotics targeting resistant pathogens remain uncertain but could influence manufacturing and R&D investments.
Key Takeaways
- XERAVA (eravacycline) operates in a niche market with high unmet needs related to antibiotic resistance.
- Current pricing approaches reflect its premium positioning; discounts are common in hospital contracts.
- Market penetration remains limited but is poised for growth with expanded indications and clinical demand.
- Total sales for 2023-2025 are projected to stay under $50 million, with significant growth depending on additional approvals and clinical trial outcomes.
- Price stabilization is expected around $1,600 per vial in the medium term, influenced by competition and healthcare policy trends.
FAQs
-
What are the primary markets for NDC 58151-0355?
Hospitals in the U.S. and globally treating complicated intra-abdominal infections with a focus on resistant bacteria.
-
How does the price of XERAVA compare to other antibiotics?
It is significantly higher, with a typical price of around $1,950 per vial, while common broad-spectrum antibiotics cost under $200.
-
Are there plans for generic or biosimilar versions?
No current plans; development of biosimilars or generics would likely occur after patent expiration, expected post-2030.
-
What factors could significantly alter the pricing?
Regulatory changes, new approvals, more aggressive competition, or government policies promoting lower-cost alternatives.
-
How is the market for anti-resistant antibiotics expected to evolve?
Increased approvals, rising resistance levels, and clinical adoption are likely to expand the market, supporting higher sales.
References
[1] MarketWatch. (2023). Antibiotic Market Size & Trends.
[2] FDA. (2018). Approval of Eravacycline for cIAI.
[3] IQVIA. (2022). Global Pharmaceutical Pricing Data.
[4] Biospace. (2022). Antibiotics and Resistance Trends.
